![]() |
市場調查報告書
商品編碼
1642794
退伍軍人症桿菌檢測市場報告(按應用(水檢測、IVD 檢測)、最終用戶(診斷實驗室、醫院和診所等)和地區)2025-2033 年Legionella Testing Market Report by Application (Water Testing, IVD Testing), End User (Diagnostic Laboratories, Hospital and Clinics, and Others), and Region 2025-2033 |
2024年,全球 退伍軍人症桿菌檢測市場規模達3.665IMARC Group美元。越來越多的糖尿病、腎臟病、人類免疫缺陷病毒(HIV)、癌症或其他慢性疾病患者面臨住院風險,刺激了市場成長。
退伍軍人症桿菌是一種影響下呼吸道的感染,可導致嚴重肺炎、龐蒂亞克熱和類似流感症狀的疾病。其測試有助於識別血液、尿液和痰中是否有細菌或抗原。目前,診斷退伍軍人菌症的檢測方法有多種,包括尿液抗原、配對血清學、聚合酶鏈反應(PCR)、直接螢光抗體(DFA)染色、下呼吸道分泌物培養等。根據檢測結果,通常對患者給予大環內酯類、喹諾酮類、四環素、強力黴素、米諾環素、甲氧芐啶等抗生素治療。
50 歲以上的成年人更容易感染 退伍軍人症桿菌。因此,全球老年人口的增加是正面影響市場的主要因素之一。此外,越來越多的吸菸者和患有癌症、糖尿病、腎臟病、人類免疫缺陷病毒(HIV)或其他慢性疾病的人面臨感染和住院的風險。由於 退伍軍人症桿菌的死亡率很高,對其有效的診斷測試和治療的需求不斷增加。除此之外,引起 退伍軍人症桿菌的細菌主要存在於不同的自然和人工水生環境中,例如冷卻水塔、呼吸治療設備、噴泉、噴霧裝置、水療池以及飯店、家庭和工廠的供水系統。因此,許多國家的衛生機構正在製定有效的水安全計畫(WSP),以盡量減少 退伍軍人症桿菌在水中的擴散。這反過來又增加了在工作場所進行 退伍軍人症桿菌測試以遵守立法的需求。此外,最近針對成人社區型肺炎患者的診斷和治療策略的臨床試驗也促進了市場的成長。
水質測試
微生物培養
DFA染色
聚合酶鍊式反應
其他
體外診斷測試
血液培養
尿液抗原測試
DFA染色
聚合酶鍊式反應
其他
診斷實驗室
醫院和診所
其他
歐洲
義大利
德國
法國
西班牙
英國
俄羅斯
其他
北美洲
美國
加拿大
亞太地區
中國
日本
澳洲
韓國
印尼
新加坡
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
該行業的競爭格局也得到了檢驗,一些主要參與者包括 Abbott Laboratories、Becton、Dickinson and Company、BioMerieux SA、Bio-Rad Laboratories Inc、Eiken Chemical Co. Ltd、Quidel Corporation、Takara Bio Inc. 和賽默飛世爾科技公司
The global legionella testing market size reached USD 366.5 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 658.2 Million by 2033, exhibiting a growth rate (CAGR) of 6.66% during 2025-2033. The increasing number of individuals who have diabetes, kidney disease, human immunodeficiency virus (HIV), cancer, or other chronic illnesses, are at risk of hospitalization, which is stimulating the market growth.
Legionella is an infection affecting the lower respiratory tract, which can lead to severe pneumonia, Pontiac fever, and illness with flu-like symptoms. Its testing helps to identify the existence of bacteria or antigens in blood, urine, and sputum. Presently, various testing methods are available to diagnose Legionella disease, including urinary antigen, paired serology, Polymerase Chain Reaction (PCR), Direct Fluorescent Antibody (DFA) stain, and culture of lower respiratory secretions. As per the testing results, macrolides, quinolones, tetracycline, doxycycline, minocycline, trimethoprim and other antibiotic treatments are usually administered to patients.
Adults over the age of 50 years are more likely to develop Legionella. Consequently, the increasing geriatric population worldwide represents one of the major factors influencing the market positively. Moreover, the rising number of individuals who smoke and have cancer, diabetes, kidney disease, human immunodeficiency virus (HIV), or other chronic illnesses are at the risk of infection and hospitalization. Since the mortality rate of Legionella is high, there is an increase in the demand for its effective diagnostic tests and treatments. Besides this, Legionella-causing bacteria are majorly found in different natural and artificial aquatic environments, such as cooling towers, respiratory therapy equipment, fountains, misting devices, spa pools, and water systems in hotels, homes, and factories. As a result, health agencies of numerous countries are developing an effective water safety plan (WSP) to minimize the proliferation of Legionella in the water. This, in turn, is escalating the demand for Legionella testing in workplace buildings to comply with the legislation. Furthermore, recent clinical trials on diagnostic and treatment strategies for adult patients with community-acquired pneumonia are contributing to the growth of the market.
Water Testing
Microbial Culture
DFA Stain
PCR
Others
IVD Testing
Blood Culture
Urine Antigen Test
DFA Stain
PCR
Others
Diagnostic Laboratories
Hospital and Clinics
Others
Europe
Italy
Germany
France
Spain
United Kingdom
Russia
Others
North America
United States
Canada
Asia Pacific
China
Japan
Australia
South Korea
Indonesia
Singapore
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Becton, Dickinson and Company, BioMerieux SA, Bio-Rad Laboratories Inc, Eiken Chemical Co. Ltd, Quidel Corporation, Takara Bio Inc., and Thermo Fisher Scientific Inc.